BRCA2 and breast cancer: However, as more risk modifying variants are identified in the future, provided these have different associations with different disease subtypes in mutation carriers and confer relative risks which are greater (or smaller) than 1, having precise breast cancer subtype risks may be useful for the planning of the clinical management of both BRCA1 and BRCA2 mutation carriers.